JP2014528449A - 新規なイミダゾールキノリン系免疫系調節剤 - Google Patents

新規なイミダゾールキノリン系免疫系調節剤 Download PDF

Info

Publication number
JP2014528449A
JP2014528449A JP2014534658A JP2014534658A JP2014528449A JP 2014528449 A JP2014528449 A JP 2014528449A JP 2014534658 A JP2014534658 A JP 2014534658A JP 2014534658 A JP2014534658 A JP 2014534658A JP 2014528449 A JP2014528449 A JP 2014528449A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycle
cycloalkyl
optionally substituted
heteroatoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014534658A
Other languages
English (en)
Japanese (ja)
Inventor
リップフォード，グレイソン，ビー．
ゼップ，チャールズ，エム．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2014528449A publication Critical patent/JP2014528449A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014534658A 2011-10-04 2012-10-03 新規なイミダゾールキノリン系免疫系調節剤 Pending JP2014528449A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543082P 2011-10-04 2011-10-04
US61/543,082 2011-10-04
PCT/US2012/058566 WO2013052550A2 (en) 2011-10-04 2012-10-03 Novel imidazole quinoline-based immune system modulators

Publications (1)

Publication Number Publication Date
JP2014528449A true JP2014528449A (ja) 2014-10-27

Family

ID=48044383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534658A Pending JP2014528449A (ja) 2011-10-04 2012-10-03 新規なイミダゾールキノリン系免疫系調節剤

Country Status (8)

Country Link
US (1) US9873694B2 (cg-RX-API-DMAC7.html)
EP (1) EP2763677B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014528449A (cg-RX-API-DMAC7.html)
AU (1) AU2012318694B2 (cg-RX-API-DMAC7.html)
CA (1) CA2850932A1 (cg-RX-API-DMAC7.html)
IL (1) IL231957A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014KN00948A (cg-RX-API-DMAC7.html)
WO (1) WO2013052550A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3490983B1 (en) 2016-07-30 2021-02-17 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
KR102688509B1 (ko) 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
CN111527080B (zh) 2017-12-15 2023-09-22 百时美施贵宝公司 取代的吲哚醚化合物
DK3728252T3 (da) 2017-12-18 2023-11-13 Bristol Myers Squibb Co 4-azaindolforbindelser
CN111491930B (zh) 2017-12-19 2023-09-26 百时美施贵宝公司 可用作tlr抑制剂的经取代的吲哚化合物
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
SG11202005700SA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
US11420958B2 (en) 2017-12-20 2022-08-23 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CA3086431A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
MX2020006014A (es) 2017-12-20 2020-08-17 Bristol Myers Squibb Co Compuestos de diazaindol.
JP7597710B2 (ja) 2018-10-24 2024-12-10 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール二量体の化合物
KR102839382B1 (ko) 2018-10-24 2025-07-25 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 및 인다졸 화합물
EP3937939A4 (en) * 2019-03-15 2022-12-07 Birdie Biopharmaceuticals Inc. IMMUNOMODULATORY COMBINATIONS AND METHODS OF TREATMENT OF CANCER
WO2020227484A1 (en) 2019-05-09 2020-11-12 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
EP4041730A1 (en) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
EP4038059B1 (en) 2019-10-04 2023-09-20 Bristol-Myers Squibb Company Substituted carbazole compounds
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
WO2022221642A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds
US12441727B2 (en) 2021-07-07 2025-10-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60123488A (ja) * 1983-11-18 1985-07-02 ライカー　ラボラトリース　インコーポレーテツド １ｈ‐イミダゾ〔４，５‐ｃ〕キノリン類および１ｈ‐イミダゾ〔４，５‐ｃ〕キノリン‐４‐アミン類
WO2000009506A1 (en) * 1998-08-12 2000-02-24 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
JP2008531567A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
WO2010030785A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20100160314A1 (en) * 2006-09-05 2010-06-24 Lipford Grayson B Small Molecule Inhibitors of Toll-Like Receptor 9
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
PT1798288E (pt) 1997-05-07 2009-12-23 Schering Corp Proteínas receptoras humanas semelhantes a toll, reagentes e métodos relacionados
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
IL143929A0 (en) 1999-01-22 2002-04-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
NZ522327A (en) 2000-05-25 2004-09-24 Schering Corp Mammalian DNAX Toll-like receptor protein, DTLR 10, antibodies and medicaments made therefrom and use in treating immunological disorders
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
EP1948173B1 (en) * 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
EP2115140B8 (en) * 2007-01-31 2017-01-25 Chongxi Yu Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60123488A (ja) * 1983-11-18 1985-07-02 ライカー　ラボラトリース　インコーポレーテツド １ｈ‐イミダゾ〔４，５‐ｃ〕キノリン類および１ｈ‐イミダゾ〔４，５‐ｃ〕キノリン‐４‐アミン類
WO2000009506A1 (en) * 1998-08-12 2000-02-24 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
JP2008531567A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
US20100160314A1 (en) * 2006-09-05 2010-06-24 Lipford Grayson B Small Molecule Inhibitors of Toll-Like Receptor 9
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
WO2010030785A2 (en) * 2008-09-10 2010-03-18 Kalypsys Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016021933; Ｊｉｎｇｘｉ　Ｈｕａｇｏｎｇ Ｖｏｌ．２４（３）, 2007, ｐ．３０４-３０７ *

Also Published As

Publication number Publication date
AU2012318694B2 (en) 2016-12-22
US20140242121A1 (en) 2014-08-28
AU2012318694A1 (en) 2014-05-22
EP2763677A4 (en) 2015-05-20
IL231957A0 (en) 2014-05-28
US9873694B2 (en) 2018-01-23
WO2013052550A3 (en) 2014-05-15
IN2014KN00948A (cg-RX-API-DMAC7.html) 2015-08-21
EP2763677A2 (en) 2014-08-13
CA2850932A1 (en) 2013-04-11
WO2013052550A2 (en) 2013-04-11
EP2763677B1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
JP6093759B2 (ja) 新規の免疫系調節剤
JP2014528449A (ja) 新規なイミダゾールキノリン系免疫系調節剤
EP2713737B1 (en) Novel immune system modulators
JP2017525711A (ja) 新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用
JP2007524615A (ja) 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
CN1809357B (zh) 小分子Toll样受体(TLR)拮抗剂
JP2023512229A (ja) トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
HK1196505A (en) Novel immune system modulators

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161220